

# 13 September 2011 **RAC/A/17/2011\_Final**

# Final Agenda

# 17<sup>th</sup> meeting of the Committee for Risk Assessment 13 – 16 September 2011 Helsinki, Finland

13 September: starts at 9:00 16 September: ends at 14:00

# Item 1 – Welcome & Apologies

# Item 2 - Adoption of the Agenda

RAC/A/17/2011\_Draft\_Rev.3 For adoption

# Item 3 – Declarations of conflicts of interest to the Agenda

# Item 4 - RAC Manual of Conclusion and Recommendations

For discussion

### Item 5 – Administrative issues and information items

- a. Status report on the RAC-16 action points
- b. Outcome of written procedures
- c. Report from other ECHA bodies and activities

RAC/17/2011/18
ROOM DOCUMENT
For information

d. Streamlining of RAC procedures

# ECHA-RAC/17/2011/19 For information

e. Declaring conflicts of interest (CoI)

For information

f. Participation of Croatia in the work of RAC

RAC/17/2011/20 For agreement

# Item 6 – Requests under Article 77 (3)(c)

o Gallium arsenide

RAC/17/2011/25
ROOM DOCUMENT
For discussion and possible adoption

# Item 7 – CLH

- 7.1 CLH Dossiers for opinion adoption (substances for which opinions are adopted by written procedure before the meeting will be removed from the revised agenda)
  - a. PHMB (poly(iminoimidocarbonyl)iminohexamethylene hydrochloride) *adopted by written procedure*
  - b. Di-n-hexyl phthalate

For adoption

c. MMTC (trichloride of methyltin)

For adoption

d. EHMA (methyltin tri(2-ethylhexyl-mercaptoacetate MMT)

For adoption

e. Fenamiphos

For adoption

f. Pitch, coal tar, high temp. (CTPHT)

For discussion and possible adoption

g. Penconazole

### For discussion and possible adoption

h. Aclonifen

For discussion and possible adoption

i. Sulcotrione

For discussion and possible adoption

j. Perestane

For discussion and possible adoption

# 7.2 CLH Dossiers for first discussion (*if time allows*)

a. Nitrobenzene

For first discussion

b. N-ethyl-2-pyrrolidone (NEP)

For first discussion

c. Ammoniumpentadecafluorooctanoate (APFO)

For first discussion

d. Perfluorooctanic acid (PFOA) and its salts

For first discussion

e. P-tert-butylphenol

For first discussion

# 7.3 Appointment of RAC (co-) rapporteurs for CLH dossiers

o Appointment of RAC (co-) rapporteurs for CLH dossiers

RAC/17/2011/21
ROOM DOCUMENT
For agreement

### 7.4 General CLH issues

a. State of play of the submitted CLH dossiers

For information

b. Review of the process for developing CLH opinions

o Accordance check

For information

o Opinion development

RAC/17/2011/22
ROOM DOCUMENT
For discussion

# Item 8 – Restrictions

### 8.1 Restriction Annex XV dossiers

o Phthalates – outcome of the conformity check

For agreement

# 8.2 General restriction issues (if relevant)

Update on intended restriction dossiers

For information

b. Review of working procedures after experiences on first dossiers

For discussion

# Item 9 – Authorisation

9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV

RAC/17/2011/23

**ROOM DOCUMENT** 

For agreement

### 9.2 Joint RAC&SEAC session

Cooperation between RAC and SEAC during the opinion development

For discussion

9.3 Follow-up of the joint RAC-SEAC session

For discussion

9.4 Follow-up of previous RAC discussions on opinions on authorisation applications

For discussion

# **Item 10 – Guidance issues**

- a. Feedback from guidance consultations
- b. Report on other guidance activities

For information

# Item 11 – Any other business

• New graduate scheme in the field of EU chemical policies at ECHA

RAC/17/2011/24
ROOM DOCUMENT
For information

# Item 12 – Main conclusions and Action Points of RAC-17

• Table with main conclusions and action points from RAC- 17

For adoption

o0o

#### PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-17

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

#### Some discussions may require a closed session

# **Tuesday 13 September: Morning Session**

- Item 1 Welcome & Apologies
- Item 2 Adoption of the Agenda
- Item 3 Declarations of conflicts of interest to the Agenda
- Item 5 Administrative issues and information items
- Item 6 Requests under Article 77 (3)(c): Gallium arsenide

### Item 7.4 – General CLH issues

State of play of the submitted CLH dossiers

Review of the process for developing CLH opinions

- Accordance check
- o Opinion development

### **Tuesday 13 September: Afternoon Session**

#### Item 7 – CLH

Item 7.1 – CLH Dossiers for opinion adoption (substances for which opinions are adopted by written procedure before the meeting will be removed from the revised agenda)

MMTC (trichloride of methyltin)

EHMA (methyltin tri(2-ethylhexyl-mercaptoacetate MMT)

Di-n-hexyl phthalate

Fenamiphos

Pitch, coal tar, high temp. (CTPHT)

Penconazole

### Tuesday 13 September: Ad-hoc groups after the plenary session if needed

Maximum 3 ad-hoc groups in parallel, to be decided depending on the discussions at the meeting.

### Wednesday 14 September: Morning Session

Optional – 7.1 CLH Dossiers for adoption: second discussion on CLH dossiers for adoption as needed.

Item 7.1 – CLH Dossiers for opinion adoption (cont.)

Aclonifen

Sulcotrione

Perestane

Item 7.2 – CLH Dossiers for first discussion (*if time allows*)

Optional – Item 6 – Requests under Article 77 (3)(c): second discussion if needed

o Gallium arsenide

### Wednesday 14 September: Afternoon Session

Optional Item 7.1 – CLH Dossiers for opinion adoption (cont.)

Optional – 7.1 CLH Dossiers for adoption: second discussion on CLH dossiers for adoption as needed

Item 7.2 – CLH Dossiers for first discussion (*if time allows*) (cont.)

Optional – Item 6 – Requests under Article 77 (3)(c): second discussion if needed

o Gallium arsenide

# Wednesday 14 September: Ad-hoc groups after the plenary session if needed

Maximum 3 ad-hoc groups in parallel, to be decided depending on the discussions at the meeting.

### **Thursday 15 September: Morning Session**

### **Item 8 – Restrictions**

Item 8.1 Restriction Annex XV dossiers

o Phthalates – outcome of the conformity check

Item 8.2 General restriction issues (if relevant)

- c. Update on intended restriction dossiers
- d. Review of working procedures after experiences on first dossiers

Optional – 7.1 CLH Dossiers for adoption: second discussion on CLH dossiers for adoption as needed.

Optional – 7.2 CLH Dossiers for first discussion (*if time allows*) (cont.)

Item 4 – RAC Manual of Conclusion and Recommendations

# Thursday 15 September: Afternoon Session

**Item 9 – Authorisation** 

Item 9.2 Joint RAC&SEAC session

Cooperation between RAC and SEAC during the opinion development

# Thursday 15 September: Ad-hoc groups after the plenary session (if needed)

1. Maximum 3 ad-hoc groups in parallel, to be decided depending on the discussions at the meeting

# Friday 16 September: Morning Session

Optional - 8.1 Restriction Annex XV dossiers (second discussion if needed)

o Phthalates – outcome of the conformity check

Optional – 7.1 CLH Dossiers for adoption: second discussion on CLH dossiers for adoption as needed.

# Item 9 – Authorisation

- Item 9.3 Follow-up of the joint RAC-SEAC session
- Item 9.4 Follow-up of previous RAC discussions on opinions on authorisation applications
- Item 9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV

# Item 7.3 – Appointment of RAC (co-) rapporteurs for CLH dossiers

# Item 12 – Main conclusions and Action Points of RAC-17

Item 10 – Guidance issues

Item 11 – Any other business